The CAPTIS® Study - Embolic Protection in TAVR

NCT ID: NCT04659538

Last Updated: 2022-05-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-24
• Study Completion Date: 2022-05-03

Brief Summary

This is a First in Human study with the Filerlex CAPTIS device designed to demonstrate the safety and feasibility of the device in subjects undergoing Transcatheter Aortic Valve Replacement (TAVR)

Detailed Description

This is a prospective, multi center, single arm, FIH safety and feasibility study enrolling up to 20 patients. Patients undergoing clinically indicated TAVR who comply with the study inclusion/exclusion criteria will be enrolled to have embolic protection with the CAPTIS® Device during the TAVR procedure.

Screening activities will include initial screening by the site, analysis of patient CT scan by the sponsor and core-lab, and review of the clinical and imaging data by an eligibility committee to confirm that all inclusion/exclusion criteria are met. Final eligibility for study enrollment is then determined by the investigator in the cardiac catheterization laboratory.

Enrolled patients will undergo safety assessment during the procedure, post-procedure, and at 30 days post-procedure; Feasibility evaluation will be assessed during procedure.

Conditions

Transcatheter Aortic Valve Replacement

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

CAPTIS Embolic Protection

TAVR will be performed according to standard institutional practice under local or general anesthesia by the transfemoral approach. The investigational device will be advanced and deployed across the aortic arch covering the ostia of the 3 great vessels (innominate, left carotid, and left-subclavian arteries) at the initiation of the procedure and withdrawn at the completion of the TAVR procedure.

Group Type: EXPERIMENTAL

CAPTIS Embolic Protection device

Intervention Type: DEVICE

The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.

Interventions

CAPTIS Embolic Protection device

The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The patient must be ≥18 years of age.

2. Patient has clinical indications for TAVR procedure.

3. TAVR procedure planned with femoral artery access site

4. TAVR device approved for use in the US, Europe or Israel

5. Femoral and iliac artery with a minimal luminal diameter of at least 6 mm

6. Descending Aorta diameter of 20 to 27mm measured 10cm from the left subclavian, determined by CT scan analysis

7. The distance between the innominate and left-subclavian arteries (including their lumens) is less than 65mm

8. Patient is willing to comply with protocol-specified preprocedure and follow-up evaluations.

9. The patient has been informed of the nature of the trial, agrees to its provisions and has provided written informed consent as approved by the ethics committee of the clinical site.

Exclusion Criteria

General

1. Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test

2. Hemodialysis shunt, graft, or arterio-venous fistula involving the lower extremity vasculature

3. Blood dyscrasias: WBC <5000/microliter, Hb <10.0 mg/dL, PLT <100,000/microliter, history of bleeding diathesis, coagulopathy, or conditions associated with increased thrombogenicity

4. Hemodynamic instability requiring pharmacological or mechanical circulatory support. Patient in whom hemodynamic instability is expected or at increased risk, will also be excluded.

5. Any surgery or procedure (including endovascular) planned for the 30 days post TAVR

6. Severe left-ventricle dysfunction with LVEF ≤30%

7. Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation

8. Active or recent bacterial endocarditis

9. Active peptic ulcer or upper GI bleeding within the prior 3 months

10. A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, clopidogrel, ticagrelor, or contrast media, which cannot be adequately pre-medicated or replaced by an alternative agent

11. Renal insufficiency (GFR < 30). Patients on renal replacement therapy (dialysis) can be enrolled into the study.

12. Life expectancy < 12 months due to non-cardiac comorbid conditions

13. Patients who refuse blood transfusion

14. Chronic or persistent atrial fibrillation, frequent recurring atrial fibrillation, and patients with planned ablation for atrial fibrillation

15. Currently participating in another investigational drug or device study

16. Patient is otherwise not appropriate for the study as determined by the investigator or the Eligibility Committee

Neurologic

17. Prior CVA or a TIA

18. Patient has undergone carotid stenting or carotid endarterectomy within the previous 6 months

19. Patient has active major psychiatric disease that prevent a conscious consent

20. Patient with neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic deficit or known structural brain abnormalities

Vascular

21. Severe tortuosity or luminal diameter of less than 6 mm of the femoral or iliac arteries

22. Excessive tortuosity or calcification or atherosclerosis of any segment of the aorta and iliac arteries

23. Patient whose innominate, carotid, or subclavian arteries reveals significant stenosis, ostial calcification, ectasia, dissection, or aneurysm at the ostium

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Filterlex Medical Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Wolfson Medical Center

Holon, , Israel

Rabin Medical Center

Petah Tikva, , Israel

Sheba Medical Center

Ramat Gan, , Israel

Countries

Israel

Related Links

http://filterlex.com

Sponsor website

Other Identifiers

CLD-FLX-001

Identifier Type: -

Identifier Source: org_study_id